Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lignoz Gel
- Development stage
- Unknown
- Lead developer
- Vilco Laboratories
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Lignoz Gel is a fixed-dose oral topical gel marketed by Vilco Laboratories for **aphthous stomatitis**, oral inflammation, and oral pain. Each gel contains zinc carnosine 2% w/w and lignocaine 2% w/w. Lignocaine provides local analgesia by reversibly inhibiting neuronal sodium-channel-mediated impulse conduction, while zinc carnosine is intended to support protection and repair of the oral mucosa through cytoprotective, antioxidant, and anti-inflammatory effects. ([vilcolabs.com](https://vilcolabs.com/product/new-innovative-products/lignoz-gel/))
- Brand names
- Lignoz Gel
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Lignoz Gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lignoz Gel.